Illumina launches $100M consumer genomics venture; Benitec prices a tiny IPO;

@FierceBiotech: ICYMI: Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. Story | Follow @FierceBiotech

@JohnCFierce: No surprise, coming off a $70M crossover, RegenX Bio files $100M. S-1/Report | Follow @JohnCFierce

> Sequencing giant Illumina ($ILMN) recruited Warburg Pincus, the Mayo Clinic and Sutter Hill Ventures to launch Helix, a consumer genomics company setting sail with $100 million from its founders. More

> Benitec Biopharma ($BNTC) pulled off a downsized IPO, raising just $13.8 million after pricing 1.5 million shares at $9.21 each. The company is developing gene-silencing treatments for hepatitis, cancer and age-related macular degeneration. News

Medical Device News

@FierceMedDev: UPDATED with comment from Fujifilm: FDA slaps three duodenoscope manufacturers with warning letters. Article | Follow @FierceMedDev

@EmilyWFierce: San Diego's Genalyte reeled in $44M in a Series C round for its microchip testing platform. Release | Follow @EmilyWFierce

> WSJ: New devices for rectal cancer surgery reduce need for colostomies. Story

> Illumina, LabCorp, Mayo Clinic, Warburg assemble to back latest consumer genomics entrant: Helix. Article

> FDA slaps three duodenoscope manufacturers with warning letters over related devices. Report

harma News

@FiercePharma: ICYMI yesterday: Will docs jump on new biosims? Survey shows they'll need some nudging. More | Follow @FiercePharma

@EricPFierce: Xellia decides it's best to have U.S. sales operations next to Raleigh, NC, plant it's expanding. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Mylan hopes Disney can add new magic to its allergy-fighting kingdom. FiercePharmaMarketing story | Follow @CarlyHFierce

> Big Pharma, rejoice: China aims to speed up approvals for new meds. Story

> Merck's Keytruda ready for quick FDA action on big melanoma expansion. Report

> Boehringer trumpets Spiolto quality-of-life data as it looks for its niche in COPD. Article

Drug Delivery News

> BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership. More

> Hydrogels: Study shows use in ulcerative colitis and Army invests in wound healing research. Report

> Checkmate Pharma gets $20M in Series A to develop cancer candidate with VLP platform. Story

> Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. Item

> Intersect's steroid-releasing implant meets its endpoint in bid for expanded indication. Article

Pharma Manufacturing News

> FDA castigates three Mylan sterile drug plants in warning letter. News

> Hemispherx says plant upgrade will allow it to return its genital wart treatment to market. Item

> GSK resumes production at plant where Legionella bacteria was detected. Report

> Merck manufacturing shedding another 2,600 jobs. Story

> Novo Nordisk looks at building its first U.S. insulin plant. Article

Pharma Asia News

> More scrutiny for Japanese duodenoscope makers on notification failures. Report

> India's Lee Pharma turned down on CL challenge to AZ's Onglyza. Item

> Does China yuan devaluation mean more downbeat pharma earnings? Article

> Japan's Mitsui buys stake in India top drug wholesaler Keimed. Story

> Going private for WuXi PharmaTech opens dealmaking options. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.